{"id":778745,"date":"2025-12-09T17:20:01","date_gmt":"2025-12-09T17:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=778745"},"modified":"2025-12-09T17:20:01","modified_gmt":"2025-12-09T17:20:01","slug":"targeted-protein-degradation-market-to-reach-985-billion-by-2035-a-deep-dive-into-growth-drivers-and-future-trends","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/targeted-protein-degradation-market-to-reach-985-billion-by-2035-a-deep-dive-into-growth-drivers-and-future-trends_778745.html","title":{"rendered":"Targeted Protein Degradation Market to Reach $9.85 Billion by 2035: A Deep Dive into Growth, Drivers, and Future Trends"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1765267666.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Targeted Protein Degradation Market to Reach $9.85 Billion by 2035: A Deep Dive into Growth, Drivers, and Future Trends\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1765267666.jpg\" alt=\"Targeted Protein Degradation Market to Reach $9.85 Billion by 2035: A Deep Dive into Growth, Drivers, and Future Trends\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland)<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Browse 485 market data Tables and 54 Figures spread through 371 Pages and in-depth TOC on &#8220;Targeted Protein Degradation Market &#8211; Global Forecast to 2035<\/div>\n<p style=\"text-align: justify;\"><strong>The Next Frontier in Drug Discovery<\/strong><\/p>\n<p style=\"text-align: justify;\">In the evolving landscape of biopharmaceutical innovation, <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/targeted-protein-degradation-analysis-market-219352281.html\"><strong><strong>targeted protein degradation (TPD)<\/strong><\/strong><\/a> is emerging as one of the most revolutionary therapeutic approaches. Unlike traditional inhibitors that merely block protein activity, TPD technologies such as <strong><strong>PROTACs (Proteolysis-Targeting Chimeras)<\/strong><\/strong> and <strong><strong>molecular glues<\/strong><\/strong> completely eliminate disease-causing proteins. This breakthrough has significant implications for <strong><strong>oncology, neurodegenerative disorders, and rare diseases<\/strong><\/strong>, making it one of the most closely watched fields in precision medicine.<\/p>\n<p style=\"text-align: justify;\">According to the latest market report, the <strong><strong>global targeted protein degradation market<\/strong><\/strong>, valued at <strong><strong>US$0.01 billion in 2024<\/strong><\/strong>, surged to <strong><strong>US$0.48 billion in 2025<\/strong><\/strong> and is expected to grow at a remarkable <strong><strong>CAGR of 35.4%<\/strong><\/strong> from 2025 to 2035, ultimately reaching <strong><strong>US$9.85 billion by 2035<\/strong><\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong><strong>Market Growth Insights &amp; Trends<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">The targeted protein degradation market is experiencing exponential growth due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><strong>Priority\/Fast Track designations<\/strong><\/strong> granted by regulatory agencies.<\/li>\n<li><strong><strong>First-in-class approvals<\/strong><\/strong> expected in the near term.<\/li>\n<li><strong><strong>Multi-indication expansion<\/strong><\/strong> for oncology, immunology, and rare diseases.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">By 2035, the TPD market will be a multi-billion-dollar sector, shaping the <strong><strong>future of drug discovery<\/strong><\/strong> and <strong><strong>precision medicine<\/strong><\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><strong>Key Trend Highlights<\/strong><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing collaborations between <strong><strong>biotech and pharma companies<\/strong><\/strong> for TPD pipeline development.<\/li>\n<li>Expansion of clinical trials for <strong><strong>oncology-focused protein degraders<\/strong><\/strong>.<\/li>\n<li>Adoption of <strong><strong>AI-driven drug discovery<\/strong><\/strong> in identifying new degrader targets.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download PDF Brochure: <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=219352281&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=targetedproteindegradationmarket\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=219352281<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><strong>Key Drivers of Market Growth<\/strong><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong><strong>Breakthrough Therapeutic Potential<\/strong><\/strong> &ndash; PROTACs and molecular glues address &ldquo;undruggable&rdquo; proteins that traditional small molecules cannot.<\/li>\n<li><strong><strong>Regulatory Acceleration<\/strong><\/strong> &ndash; FDA and EMA fast-track designations are expediting approvals.<\/li>\n<li><strong><strong>Expanding Clinical Pipeline<\/strong><\/strong> &ndash; More than 100+ TPD candidates are currently in preclinical and clinical stages.<\/li>\n<li><strong><strong>Strategic Collaborations<\/strong><\/strong> &ndash; Big pharma companies like <strong><strong>Pfizer, Novartis, and Merck<\/strong><\/strong> are heavily investing in targeted protein degradation partnerships.<\/li>\n<li><strong><strong>Rising Oncology Burden<\/strong><\/strong> &ndash; Cancer treatment is expected to be the leading application area for protein degraders.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong><strong>Challenges &amp; Opportunities<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">While the market outlook is highly positive, challenges remain:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><strong>Manufacturing complexities<\/strong><\/strong> of bifunctional degraders (PROTACs).<\/li>\n<li><strong><strong>Limited biomarker validation<\/strong><\/strong> for certain targets.<\/li>\n<li><strong><strong>High R&amp;D costs<\/strong><\/strong> in developing next-gen degraders.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong><strong>Opportunities:<\/strong><\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Development of <strong><strong>oral bioavailable degraders<\/strong><\/strong>.<\/li>\n<li>Leveraging <strong><strong>artificial intelligence<\/strong><\/strong> to accelerate degrader design.<\/li>\n<li>Expansion into <strong><strong>autoimmune and neurodegenerative diseases<\/strong><\/strong> beyond oncology.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><strong>Competitive Landscape<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong><strong>competitive landscape of the targeted protein degradation market<\/strong><\/strong> is rapidly evolving. Key players include:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><strong>Arvinas, Inc.<\/strong><\/strong> &ndash; Pioneer in PROTAC technology.<\/li>\n<li><strong><strong>Nurix Therapeutics<\/strong><\/strong> &ndash; Strong degrader pipeline in oncology.<\/li>\n<li><strong><strong>C4 Therapeutics<\/strong><\/strong> &ndash; Advancing multiple protein degrader candidates.<\/li>\n<li><strong><strong>Kymera Therapeutics<\/strong><\/strong> &ndash; Focused on immunology and oncology.<\/li>\n<li><strong><strong>Pfizer, Novartis, and Merck<\/strong><\/strong> &ndash; Strategic collaborations with biotech innovators.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages : <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=219352281&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=targetedproteindegradationmarket\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=219352281<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><strong>Future Outlook: Targeted Therapies by 2035<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">Looking ahead, the targeted protein degradation market is set to <strong><strong>redefine drug development<\/strong><\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li>First <strong><strong>FDA approvals for PROTAC-based therapies<\/strong><\/strong> are anticipated before 2030.<\/li>\n<li>Expansion of TPD into <strong><strong>rare diseases and neurology<\/strong><\/strong>.<\/li>\n<li>Greater adoption of <strong><strong>AI, machine learning, and computational biology<\/strong><\/strong> to accelerate degrader discovery.<\/li>\n<li>Emergence of <strong><strong>next-generation molecular glues<\/strong><\/strong> with broader applications.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">By 2035, <strong><strong>protein degraders<\/strong><\/strong> will move from niche innovation to <strong><strong>mainstream therapeutic class<\/strong><\/strong>, reshaping the <strong><strong>global precision medicine market<\/strong><\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong><strong>Conclusion: The Time to Invest in Protein Degraders is Now<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong><strong>targeted protein degradation market<\/strong><\/strong> represents one of the most promising opportunities in <strong><strong>biopharma innovation<\/strong><\/strong>. With a projected market size of <strong><strong>US$9.85 billion by 2035<\/strong><\/strong>, fueled by <strong><strong>regulatory momentum, scientific breakthroughs, and strong investor interest<\/strong><\/strong>, now is the time for businesses, researchers, and investors to engage with this transformative field. <strong><strong>Are you ready to harness the future of targeted protein degradation?<\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><strong>Frequently Asked Questions (FAQ)<\/strong><\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong><strong>What is targeted protein degradation?<\/strong><\/strong>Targeted protein degradation (TPD) is a novel therapeutic strategy that eliminates disease-causing proteins using technologies like PROTACs and molecular glues.<\/li>\n<li><strong><strong>How big is the targeted protein degradation market?<\/strong><\/strong>The market is projected to grow from<strong><strong>US$0.48 billion in 2025<\/strong><\/strong>to <strong><strong>US$9.85 billion by 2035<\/strong><\/strong>, at a CAGR of 35.4%.<\/li>\n<li><strong><strong>Which companies are leading in the TPD market?<\/strong><\/strong>Arvinas, Nurix Therapeutics, C4 Therapeutics, Kymera Therapeutics, Pfizer, Novartis, and Merck are key players.<\/li>\n<li><strong><strong>What are the main drivers of TPD growth?<\/strong><\/strong>Regulatory fast-track designations, expanding clinical pipelines, oncology applications, and strategic pharma-biotech collaborations.<\/li>\n<li><strong><strong>What is the future outlook for protein degraders?<\/strong><\/strong>By 2030, the first PROTAC-based therapies are expected to hit the market, with expansion into neurology, immunology, and rare diseases by 2035.<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=targeted-protein-degradation-market-to-reach-985-billion-by-2035-a-deep-dive-into-growth-drivers-and-future-trends\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/targeted-protein-degradation-analysis-market-219352281.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/targeted-protein-degradation-analysis-market-219352281.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=targeted-protein-degradation-market-to-reach-985-billion-by-2035-a-deep-dive-into-growth-drivers-and-future-trends\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland) Browse 485 market data Tables and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/targeted-protein-degradation-market-to-reach-985-billion-by-2035-a-deep-dive-into-growth-drivers-and-future-trends_778745.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-778745","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=778745"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778745\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=778745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=778745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=778745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}